Through cased-based learning, the program emphasizes the real-world application of molecular testing, including how to interpret biomarker results and integrate them into treatment.  Key trials such as SOLO-1, PAOLA-1, PRIMA, DUO-E and ARIEL3 will be discussed to illustrate evidence-based approaches to selecting the right therapy for the right patient, particularly in the context of PARP inhibitor use and HRD testing as well as target based ADCs.  The course acknowledges geographic disparities, particularly in areas with limited on-the-ground support and aims to provide practical guidance for clinicians who are working to implement testing and treatment strategies under local constraints.  Additionally, the program will explore emerging therapeutic targets and biomarkers, including the potential of antibody-drug conjugates (ADCs), Her2 and Folate Receptor Alpha, and discuss how evolving science is reshaping treatment landscapes. Consideration will be given to health equity, access to testing, and the implementation challenges faced by clinicians and patients across diverse care environments.

All content will be aligned with current regulatory guidelines and appropriate for independent medical education (IME), with a clear distinction between on-label use and emerging data requiring further validation.

Participants will receive an in-depth overview of the biological basis of ctDNA detection, the current clinical evidence supporting its utility, and its integration into clinical workflows. Case-based discussions will illustrate real-world applications, showcasing how ctDNA can optimize decisions on surveillance and therapeutic strategy. The program will also critically assess limitations and challenges of ctDNA-based MRD testing, including issues with sensitivity, false positives, access, and cost.

In alignment with a fair and balanced approach, the course will also explore other MRD detection modalities such as radiologic imaging, CA-125, and histopathology, highlighting comparative strengths and contexts for use. The program engages clinicians to learn how to interpret ctDNA MRD data and apply it effectively within a multidisciplinary care framework.

Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making.  This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear.

This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.